Botanical extract compositions and methods of use

A technology of composition and extract, which is applied in the field of treating cancer and estrogen-related disorders, and can solve problems such as no effect on advanced prostate cancer

Inactive Publication Date: 2007-06-20
MEDICAL RES & EDUCATION ASSOCS
View PDF1 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although chemotherapy is often the option for men with advanced br

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Botanical extract compositions and methods of use
  • Botanical extract compositions and methods of use
  • Botanical extract compositions and methods of use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] This example shows the activity of wogonin and isoliquiritigenin in inhibiting the growth of hormone-sensitive prostate cancer cell line LNCAP cells.

[0106]The MTT assay (MTT is 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was used to count viable cell numbers. Detection reagents were purchased from Boehringer Mannheim (Roche Diagnosis Corp, Indianapolis, Indiana). In this assay, the tetrazolium dye MTT is separated into formazan by metabolically active cells and exhibits strong absorption at 550-618 nm. Protocols for cell survival experiments were provided by the manufacturers of the reagents and were further modified by our laboratory as follows.

[0107] Prostate cancer cells or breast cancer cells were seeded in 96-well microtiter plates at a cell density of 3×103 cells (MCF-7) or 6×103 cells (LNCAP or DU145), respectively, and the volume of culture medium was 100 μl . After 24 hours of incubation, 20 microliters of solutions containing differe...

Embodiment 2

[0118] This example shows the activity of isoliquiritigenin in inhibiting the growth of the breast cancer cell line MCF-7.

[0119] The efficacy of isoliquiritigenin on MCF-7 cells was evaluated using the same protocol as described in the Examples. MCF-7 cells are breast cancer cells expressing estrogen receptors. Therefore, it is a good model for studying the effect of antineoplastic drugs on estrogen receptor positive breast cancer.

[0120] Figure 9 shows the MTT experimental curve of isoliquiritigenin on MCF-7 cells. The data showed that isoliquiritigenin inhibited the growth of MCF-7 cells, and a dose-dependent curve was observed. Its ED50 value is shown in column 3 of Table 1.

Embodiment 3

[0122] This example shows the regulatory effect of wogonin and isoliquiritigenin on the cell cycle of LNCaP. LNCAP cells have a hormone-dependent cell cycle.

[0123] Preparation of cell cycle assay samples: cells cultured in 12.5cm2 size flasks (2-4×10 6 cells) were exposed to two concentrations of wogonin and isoliquiritigenin for 24-48 hours before collection. Cells were washed with PBS buffer and fixed in ice-cold 70% ethanol. The fixed cells were extracted, redissolved in PBS solution, and then washed with 1.0 mg / ml DAPI (4,6-diamidino-2-phenylindole, purchased from Eastman Kodak, Rochester, NY (Issey, Rochester, New York). Terman Kodak) stained, and dissolved in as previously described by Halicka et al. by Extracts of the Chinese Herbal Preparation of PC SPES ", INTERNATIONAL J.OF ONCOLOGY (1997), 11:437-448) pH 6.8 containing 100mM NaCl, 2mM MgCl2, and 10mM of 0.1% Triton X-100 (Sigma) piperazine-N,N-bis-2-ethanesulfonic acid buffer.

[0124] Intracellular DNA cont...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A composition having phytoestrogenic and anti-cancer activity is described. The composition comprises wogonin, isoliquiritigenin, coumestrol, their pharmaceutically acceptable salts or esters, their selectively substituted analogs, or combinations thereof. The compositions may also include an anti-cancer agent and/or an immune stimulant. A method for treating or preventing cancer or an estrogen related disorder includes administering a therapeutically effective amount of the compositions is described. The compositions are particularly useful in the treatment of hormone-related cancers.

Description

technical field [0001] The present invention relates to a composition of plant extracts and a method for treating human body, especially a method for treating cancer and estrogen-related disorders. Background technique [0002] Plant extracts, phytoestrogens, such as the isoflavones found in soy products, are thought to have the potential to treat and prevent disease. In particular, phytoestrogens are believed to be effective in treating estrogen-related disorders such as osteoporosis, menopause (menopause) symptoms, and hormone-related cancers. [0003] Endogenous and exogenous hormones have been reported to play a role in the development of hormone-related cancers, such as breast, colon, lung, endometrial, ovarian, prostate, bladder, testicular, thyroid, and bone cancers. Carcinoma (see, eg, Henderson et al, "Hormonal cancerogenesis", CARCINOGENESIS (2000), 21(3):427-433). [0004] Epidemiological studies have shown that consumption of foods high in phytoestrogens, such ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61K31/122A61K31/37A61K36/539A61K45/06A61K35/00
Inventor 索菲·陈
Owner MEDICAL RES & EDUCATION ASSOCS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap